Effects on quality of life of L-carnitine administration in covert hepatic encephalopathy

Not Applicable

Recruiting

• Conditions: Diseases of the digestive system

• Registration Number: KCT0002029
• Lead Sponsor: Hanyang University Seoul Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 11 March 2019

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

1. Age : 19-65 years old
2. Hepatitis B associated cirrhosis
3. Covert hepatic encephalopathy (Minimal hepatic HE or West Heaven Grade I )
4. Informed consent

Exclusion Criteria

1. History of overt hepatic encephalopathy (West Heave grade II or more)
2. History of psychiatric or neurologic disease
3. Malignant tumor (except well controlled hepatocellular carcinoma)
4. Viable hepatocelluar carcinoma
5. Recent upper gastrointestinal bleeding within 6 months
6. Immune suppressive agent medication
7. ALT > 400 IU/L
8. Serum creatinin > 1.5 mg/dl
9. Hypersensitivity to carnitine
10. Significant alcohol consumption ( male > 210 g/week, female> 140 g/week)
11. Women who want to pregnant
12. Pregnant women
13. Join recent another clinical trial within 1 month.

Study & Design

• Study Type: Interventional Study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ife of quality

Secondary Outcome Measures

Name	Time	Method
Covert hepatic encephalopathy;Liver function (The Model for End-Stage Liver Disease, Child score)